Forteo

 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2003-2018
02420032018

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Amgen and collaborators UCB Pharma have said their investigational osteoporosis agent romosozumab met its main goal in late-stage… (More)
Is this relevant?
2016
2016
Amgen and collaborators UCB Pharma have said their investigational osteoporosis agent romosozumab met its main goal in late-stage… (More)
Is this relevant?
2014
2014
An efficient methodology for ligation at glutamate (Glu) is described. A γ-thiol-Glu building block was accessed in only three… (More)
Is this relevant?
2013
2013
 
  • table 1
  • table 2
Is this relevant?
2011
2011
There is no disease-modifying therapy for osteoarthritis, a degenerative joint disease that is projected to afflict more than 67… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Review
2011
Review
2011
Drug-associated osteonecrosis of the jaws (ONJ) remains a timely topic, a frequent occurrence, and a difficult condition to… (More)
Is this relevant?
Review
2011
Review
2011
OBJECTIVE The objective of this study was to present a comprehensive model for the pathogenesis of bisphosphonate-associated… (More)
Is this relevant?
2009
2009
Combination therapy with daily teriparatide (Forteo, Eli Lilly) and a once-yearly 5-mg zoledronic acid injection (Reclast… (More)
  • table 1
Is this relevant?
2009
2009
Chronic kidney disease (CKD) is commonly, if not universally, associated with derangements in bone and mineral metabolism… (More)
Is this relevant?
Review
2005
Review
2005
There are three injectable and one oral bone-building (i.e., bone anabolic) parathyroid hormone (PTH) peptides. One of the four… (More)
Is this relevant?